NVCT Stock Analysis: Buy, Sell, or Hold?
NVCT - Nuvectis Pharma, Inc. Common Stock
$7.45
-0.03 (-0.40%)
▼
5d:
-9.81%
30d:
-15.91%
90d:
-3.87%
HOLD
LOW Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 05, 2026
Smart Money Accumulation
NVCT is down 8.8% this week, but smart money is accumulating calls. Top strike: $7.5 2026-04-17 with 1,433 OI. Call ratio: 100% View Scanner →
Strength: 9.4/10
Get Alerted When NVCT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NVCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NVCT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NVCT is currently trading at $7.45, which is considered oversold relative to its 30-day fair value range of $8.07 to $9.14.
Technical Outlook: Technically, NVCT is in a strong uptrend. The price is currently testing key support at $7.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.80 (+124.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NVCT is in a strong uptrend. The price is currently testing key support at $7.41. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $16.80 (+124.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$8.07 -
$9.14
Company Quality Score
59/100
(HOLD)
Options IV Signal
37th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 37th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 124.6% below Wall St target ($16.80)
- CAUTION: Recommendation downgraded due to -9.8% 5-day decline
Fair Price Analysis
30-Day Fair Range
$8.07 -
$9.14
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.97
(13.1%)
Support & Resistance Levels
Support Level
$7.41
Resistance Level
$9.30
Current Trend
Strong Uptrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.68
Wall Street Target
$16.80
(+124.6%)
Share & Embed Analysis
Last updated: March 30, 2026 11:37 AM ET
Data refreshes hourly during market hours. Next update: 12:37 PM
Data refreshes hourly during market hours. Next update: 12:37 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NVCT showing a specific setup today?
Insider Activity (6 Months)
6
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Juan Sanchez
BUY
13000 shares
2025-11-05
Matthew L Kaplan
BUY
11000 shares
2025-11-05
Ron Bentsur
BUY
5000 shares
2025-11-05
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 65 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$89 | 54 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1018 | 56 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$58 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$84 | 53 HOLD |
